Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System
Objective: To evaluate effectiveness and safety profile of pemetrexed in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when it´s used on real clinical practice in Andalusia (a Spanish region with 8.5 million inhabitants, 2014 census data). Methods: An observational...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-11-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/10424.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846093800727904256 |
|---|---|
| author | María Antonia Pérez-Moreno Jesús Cotrina-Luque Mercedes Galván-Banqueri Sandra Flores-Moreno Francisco Javier Bautista-Paloma Miguel Ángel Calleja-Hernández |
| author_facet | María Antonia Pérez-Moreno Jesús Cotrina-Luque Mercedes Galván-Banqueri Sandra Flores-Moreno Francisco Javier Bautista-Paloma Miguel Ángel Calleja-Hernández |
| author_sort | María Antonia Pérez-Moreno |
| collection | DOAJ |
| description | Objective: To evaluate effectiveness and safety profile of pemetrexed in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when it´s used on real clinical practice in Andalusia (a Spanish region with 8.5 million inhabitants, 2014 census data). Methods: An observational multicentre retrospective study was conducted. Adult patients with locally advanced/metastatic NSCLC who received pemetrexed in any hospital in the Andalusian Public Health System during the last term of 2011 were included. We collected patients´ baseline characteristics, diagnostic and treatment data, effectiveness variables (response to treatment with pemetrexed and overallsurvival) and main adverse reactions detected. Results: 172 patients from 17 hospitals were included (77.33% were men), median age 63 years old (between 34 and 83). The predominant histology was adenocarcinoma (84.30%) and 85.20% were diagnosed of lung cancer with IV-stage. 78.49% had been smokers at some point in their lives. Median overall survival from the start of pemetrexed was 9 months (95%CI, 4.1-13.9). Progression of the disease was the most frequent response (33.14%), only one patient had complete response. Stable disease was associated with a higher probability of survival. Main adverse reactions detected were asthenia, haematological reactions, gastrointestinal reactions and termal o mucous toxicity. No patients discontinued treatment for serious toxicity. Conclusions: Pemetrexed resulted quite effective in NSCLC when it was used on real clinical practice, with higher survival in non-squamous histology and patients with the best score of Eastern Cooperative Oncology Group scale. The toxicity profile was well tolerated. Prospective studies would be needed to confirm the effect of prognostic factors observed |
| format | Article |
| id | doaj-art-aedda44e3b8b4764b68dbecae94ca475 |
| institution | Kabale University |
| issn | 1130-6343 2171-8695 |
| language | English |
| publishDate | 2016-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Farmacia Hospitalaria |
| spelling | doaj-art-aedda44e3b8b4764b68dbecae94ca4752025-01-02T16:24:39ZengElsevierFarmacia Hospitalaria1130-63432171-86952016-11-0140647748510.7399/fh.2016.40.6.10424Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health SystemMaría Antonia Pérez-Moreno0Jesús Cotrina-Luque1Mercedes Galván-Banqueri2Sandra Flores-Moreno3Francisco Javier Bautista-Paloma4Miguel Ángel Calleja-Hernández5Hospital Pharmacist. Pharmacy Department Hospital Universitario Virgen del Rocío, Seville.Hospital Pharmacist. Pharmacy Department Hospital Universitario Virgen del Rocío, SevilleHospital Pharmacist. Pharmacy Department Hospital Universitario Virgen del Rocío, SevilleHospital Pharmacist. Pharmacy Department Hospital Universitario Virgen del Rocío, SevilleHospital Pharmacist. Pharmacy Department Hospital Universitario Virgen del Rocío, SevilleHospital Pharmacist. Pharmacy Department. Hospital Universitario Virgen de las Nieves, Granada. SpainObjective: To evaluate effectiveness and safety profile of pemetrexed in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when it´s used on real clinical practice in Andalusia (a Spanish region with 8.5 million inhabitants, 2014 census data). Methods: An observational multicentre retrospective study was conducted. Adult patients with locally advanced/metastatic NSCLC who received pemetrexed in any hospital in the Andalusian Public Health System during the last term of 2011 were included. We collected patients´ baseline characteristics, diagnostic and treatment data, effectiveness variables (response to treatment with pemetrexed and overallsurvival) and main adverse reactions detected. Results: 172 patients from 17 hospitals were included (77.33% were men), median age 63 years old (between 34 and 83). The predominant histology was adenocarcinoma (84.30%) and 85.20% were diagnosed of lung cancer with IV-stage. 78.49% had been smokers at some point in their lives. Median overall survival from the start of pemetrexed was 9 months (95%CI, 4.1-13.9). Progression of the disease was the most frequent response (33.14%), only one patient had complete response. Stable disease was associated with a higher probability of survival. Main adverse reactions detected were asthenia, haematological reactions, gastrointestinal reactions and termal o mucous toxicity. No patients discontinued treatment for serious toxicity. Conclusions: Pemetrexed resulted quite effective in NSCLC when it was used on real clinical practice, with higher survival in non-squamous histology and patients with the best score of Eastern Cooperative Oncology Group scale. The toxicity profile was well tolerated. Prospective studies would be needed to confirm the effect of prognostic factors observedhttp://www.aulamedica.es/fh/pdf/10424.pdfpetremexNon-small-cell lung cancerEffectivenessSafety |
| spellingShingle | María Antonia Pérez-Moreno Jesús Cotrina-Luque Mercedes Galván-Banqueri Sandra Flores-Moreno Francisco Javier Bautista-Paloma Miguel Ángel Calleja-Hernández Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System Farmacia Hospitalaria petremex Non-small-cell lung cancer Effectiveness Safety |
| title | Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System |
| title_full | Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System |
| title_fullStr | Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System |
| title_full_unstemmed | Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System |
| title_short | Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System |
| title_sort | effectiveness and safety of pemetrexed for non small cell lung cancer in the andalusian public health system |
| topic | petremex Non-small-cell lung cancer Effectiveness Safety |
| url | http://www.aulamedica.es/fh/pdf/10424.pdf |
| work_keys_str_mv | AT mariaantoniaperezmoreno effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem AT jesuscotrinaluque effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem AT mercedesgalvanbanqueri effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem AT sandrafloresmoreno effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem AT franciscojavierbautistapaloma effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem AT miguelangelcallejahernandez effectivenessandsafetyofpemetrexedfornonsmallcelllungcancerintheandalusianpublichealthsystem |